These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35438134)

  • 21. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
    Sung YK; Lee YH
    J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expanded Table: Some biologic drugs and JAK inhibitors for rheumatoid arthritis.
    Med Lett Drugs Ther; 2021 Nov; 63(1637):e187-e189. PubMed ID: 35085212
    [No Abstract]   [Full Text] [Related]  

  • 23. [JAK inhibitors in rheumatology].
    Cantagrel A
    Rev Prat; 2022 Nov; 72(9):935-940. PubMed ID: 36512005
    [No Abstract]   [Full Text] [Related]  

  • 24. Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients.
    Tóth L; Juhász MF; Szabó L; Abada A; Kiss F; Hegyi P; Farkas N; Nagy G; Helyes Z
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of upadacitinib in rheumatoid arthritis.
    Tanaka Y
    Mod Rheumatol; 2020 Sep; 30(5):779-787. PubMed ID: 32530345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoglycaemia following JAK inhibitor treatment in patients with diabetes.
    van Lint JA; van Hunsel FPAM; Tas SW; Vonkeman HE; Hoentjen F; van Doorn MBA; Hebing RCF; Nurmohamed MT; van den Bemt BJF; van Puijenbroek EP; Jessurun NT
    Ann Rheum Dis; 2022 Apr; 81(4):597-599. PubMed ID: 34916208
    [No Abstract]   [Full Text] [Related]  

  • 27. Reply to "Letter to the Editor": Exploring Multidimensional Factors of Herpes Zoster Risk in Rheumatoid Arthritis Patients Undergoing JAK Inhibitor Treatment.
    Chen DY
    Clin Rheumatol; 2024 Sep; 43(9):3035. PubMed ID: 39093522
    [No Abstract]   [Full Text] [Related]  

  • 28. Patients' safety skills assessment with biologics and JAK inhibitors: Update of the BioSecure questionnaire.
    Beauvais C; Gaud-Listrat V; Sellam J; Fayet F; Béranger M; Deparis N; Antignac M; Sordet C; Rodère M; Gossec L
    Joint Bone Spine; 2021 Oct; 88(5):105215. PubMed ID: 33992790
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical significance of Janus Kinase inhibitor selectivity.
    Choy EH
    Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy and safety of JAK inhibitors and leflunomide in rheumatoid arthritis: A protocol for systematic review and meta-analysis.
    Zhang X; Zhang M; Wang Z; Liu Y; Feng X; Yang L; Wang Y; Liu J; Zhao D
    Medicine (Baltimore); 2022 Dec; 101(49):e32154. PubMed ID: 36626515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis.
    Singh S; Singh S
    Int Immunopharmacol; 2020 Sep; 86():106731. PubMed ID: 32590315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis.
    Kotyla PJ; Islam MA; Engelmann M
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis.
    Łączna M; Malinowski D; Paradowska-Gorycka A; Safranow K; Dziedziejko V; Pawlik A
    Eur J Clin Pharmacol; 2021 Nov; 77(11):1673-1678. PubMed ID: 34160668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Which should be first: biologic DMARDs or Janus kinase inhibitors?
    Koike T
    Rheumatology (Oxford); 2023 May; 62(5):1738-1739. PubMed ID: 36355459
    [No Abstract]   [Full Text] [Related]  

  • 36. How effective are JAK-inhibitors? Perspectives from clinical trials and real-world studies.
    Lauper K; Hyrich KL
    Expert Rev Clin Immunol; 2022 Mar; 18(3):207-220. PubMed ID: 34528855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accelerated rheumatoid nodulosis resolved after switching to Janus kinase inhibitor therapy.
    Iinuma S; Hayashi K; Ishida-Yamamoto A
    J Dermatol; 2023 Mar; 50(3):e98-e99. PubMed ID: 36310408
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluating upadacitinib for the treatment of rheumatoid arthritis.
    Mysler E; Lizarraga A
    Expert Opin Pharmacother; 2020 Sep; 21(13):1527-1536. PubMed ID: 32515665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
    Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
    Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis.
    Alfaro-Lara R; Espinosa-Ortega HF; Arce-Salinas CA;
    Reumatol Clin (Engl Ed); 2019; 15(3):133-139. PubMed ID: 28867467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.